Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data

References

• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global Burden of Disease 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–1259. doi:10.1016/S0140-6736(17)32154-2
   PubMed Web of Science ®Google Scholar
• Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J Investig Allergol Clin Immunol. 2011;21(6):466–471.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Global Initiative for Asthma website. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed December 30, 2021.
   Google Scholar
• Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814–830. doi:10.1016/j.chest.2021.04.013.
   PubMed Web of Science ®Google Scholar
• Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–341. doi:10.1016/j.jaci.2013.04.052
   PubMed Web of Science ®Google Scholar
• de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2:2015. doi:10.1183/23120541.00100-2015
   Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021;76(1):14–44. doi:10.1111/all.14425
   PubMed Web of Science ®Google Scholar
• Pérez de Llano L, Dávila I, Martínez-Moragón E, et al. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: the FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score. J Allergy Clin Immunol Pract. 2021;9(7):2725–2731. doi:10.1016/j.jaip.2021.01.033.
   PubMed Web of Science ®Google Scholar
• Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010
   PubMed Web of Science ®Google Scholar
• Liddament M, Husten J, Estephan T, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019;11(2):291–298. doi:10.4168/aair.2019.11.2.291
   PubMed Web of Science ®Google Scholar
• Casas-Maldonado F, Álvarez-gutiérrez FJ, Blanco-Aparicio M, et al. Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map. J Asthma. 2021;17:1–11. doi:10.1080/02770903.2021.1978483
   Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Peters SP, Hill TD, et al. Clinical outcomes and health-care resource use associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice. Chest. 2021;159(5):1734–1746. doi:10.1016/j.chest.2020.11.060
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Noto A, et al. Comparability of asthma control test scores between self and physician-administered test. Respir Med. 2020;170:106015. doi:10.1016/j.rmed.2020.106015
   PubMed Web of Science ®Google Scholar
• Ibrahim H, O’Sullivan R, Casey D, et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respir Res. 2019;20(1):289. doi:10.1186/s12931-019-1251-3
   PubMed Web of Science ®Google Scholar
• Numata T, Araya J, Miyagawa H, et al. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: a Single-Center Retrospective Study. J Asthma Allergy. 2021;14:609–618. doi:10.2147/JAA.S311975
   PubMed Web of Science ®Google Scholar
• Pérez de Llano LA, Cosío BG, Domingo C, et al. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: a Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol Pract. 2019;7(7):2277–2283. doi:10.1016/j.jaip.2019.01.017
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070. doi:10.1016/j.clinthera.2016.07.010
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019;41(10):2041–2056. doi:10.1016/j.clinthera.2019.07.007
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Benfante A, et al. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. J Asthma Allergy. 2021;14:163–173. doi:10.2147/JAA.S297273
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: a Real-World Multicenter Study. J Allergy Clin Immunol Pract. 2021;9(12):4371–4380.e4. doi:10.1016/j.jaip.2021.08.004
   PubMed Web of Science ®Google Scholar
• Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901–913. doi:10.1016/j.clinthera.2011.06.001
   PubMed Web of Science ®Google Scholar